|  |  |
| --- | --- |
|  |  |
|  |

# Patient and Clinician Engagement (PACE) meeting - Company statement

|  |  |
| --- | --- |
| **Name of company:** |  |
| **Name of medicine and formulation:** |  |
| **SMC reference number:** | To Be Completed By SMC Secretariat |
| **Indication under review:** |  |
| **Company’s proposed positioning (as stated in section 1b of the New Product Assessment Form):** |  |
| **Date of scheduled PACE meeting:** |  |

Please provide a ***brief summary*** of any additional information the company wishes to be considered at the Patient and Clinical Engagement (PACE) meeting. This should cover information that may help determine the ‘added value’ of the medicine in the context of treatments currently available in NHS Scotland that may not be fully captured in conventional clinical and health economic analysis.

In particular, please focus on aspects such as:

* Severity of the condition the medicine will treat.
* Need for the medicine, including the level of unmet need and how the medicine will address it.
* Added value of the medicine for the patient and for the patient’s family / carers. This may include secondary endpoints from clinical studies e.g. those associated with functions of daily living, carer health related quality of life etc.
* Optimal place in therapy.
* Other aspects of prescribing such as continuation rules.

**Please do not exceed two pages and do not include information you consider commercial-in-confidence.**

|  |
| --- |
|  |